Controlled Substance Market

Controlled Substance Market (Drug: Opioids, Stimulants, Depressants, Cannabinoids; Application: ADHD, Pain Management, Depression, Sleep Disorder, Cough Suppression, Anxiety, Seizure, Others; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Stimulant Drugs Prove Useful for Children with ADHD and Tourette Syndrome

Stimulant medications are increasingly gaining credibility for being a safe and effective option for ADHD (Attention Deficit Hyperactivity Disorder) treatment as far as children are concerned. Improved formulations of stimulants have benefitted children in letting them focus their thoughts better and ignore distractions. Companies in the controlled substance market are teaming up with doctors and healthcare providers to combine the treatment of stimulant medications with behavior therapy to treat children suffering from ADHD. This developmental aspect has helped children pay more attention to routine activities and control their behavior.

The application of stimulants in the treatment of ADHD is estimated to increase in the coming years. ADHD accounts for the second-highest revenue amongst all applications in the controlled substance market, with a projected value of ~US$ 25 billion by the end of 2027. Due to these favorable aspects, it has been found that, the right medication of stimulants amongst ADHD patients has shown positive improvements in their behavioral patterns. Two forms of stimulants, namely, immediate release (short-acting) medications and extended release (immediate-acting and long-acting) medications are lately being talked about in the controlled substance market. The former is gaining increased popularity, since the medication is less expensive as compared to other stimulant drugs.

Stimulant drugs are even proving useful for patients with Tourette syndrome. Medications such as atomoxetine or guanfacine are safe and recommended for children to reduce conditions associated with frequent tics and unusual vocal sounds.

controlled substance market infographic

Request a sample to get extensive insights into the Controlled Substance Market

Pain Management Increases Scope of Opioid Treatment for Advanced Cancer Patients

Pain management is a necessary aspect for patients associated with advanced cancer. Thus, opioids are highly recommended for cancer patients to reduce the discomfort caused due to a diverse group of pain syndromes. Pain management is estimated to account for the highest revenue amongst all applications in the controlled substance market, with an estimated value of ~US$ 43 billion by the end of 2027. Thus, the increased prescription of opioid for advanced cancer patients is one of the major reasons for the exponential growth of pain management in the controlled substance market.

Although opioids help reduce the severity of pain syndromes, certain drawbacks of the medication are leading to resistance in its adoption amongst advanced cancer patients. Cognitive impairment and delirium are some of the few side effects caused due to the consumption of opioids. To overcome these drawbacks, healthcare companies in the controlled substance market are increasing awareness about screening in the early stages of delirium. Mini Mental State Examination and the Memorial Delirium-Assessment Scale are some of the credible tools that aid the screening procedure to assess the severity of cognitive impairment and delirium in patients.

In order to encourage advanced cancer patients to adopt opioids, companies in the controlled substance market are educating doctors and healthcare providers to thoroughly examine the complex and multi-faceted nature of pain management amongst patients.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Judicious Prescription of Tramadol to Reduce Incidence of Morbidity and Mortality

The controlled substance market is projected to grow at a healthy CAGR of ~7% during the forecast period. However, on the other hand, the limitations and adverse effects of certain drugs may hamper the growth of the controlled substance market. For instance, tramadol is an effective drug for pain relief, but confounding reasons of patients have led to instances of increased morbidity and mortality.

Tramadol has the potential for abuse and addiction. Although tramadol is being utilized and accepted in medical care, it is tightly regulated. Confounding reasons present ambiguity for the effectiveness of tramadol. Although tramadol is classified as a Schedule IV drug, lack of appropriate prescription for the drug has caused high rates of death in the controlled substance landscape. To overcome these challenges, manufacturers in the controlled substance market are increasing awareness about the judicious prescription of tramadol. They are increasing research & development to help educate doctors and patients about the potential risks of tramadol treatment.

In order to make medical research studies more authentic, companies in the controlled substance market should assess confounders to enhance the credibility of research outcomes. Healthcare companies are increasing the availability of tramadol amongst patients suffering from osteoarthritis and other painful conditions.  

controlled substance market segmentation

Stuck in a neck-to-neck competition with other brands? Request a custom report on “Controlled Substance Market” 

Analysts’ Viewpoint

Opioids are efficacious pain-reducing medications. However, strict laws and regulations dictate the prescription of opioids, since these medications are found to cause serious harm to patients, owing to their side effects. As such, healthcare companies need to work in collaboration with health commissions such as the FDA to improve enforcement on the illicit marketing of unapproved opioids, and offer access to improved treatment alternatives for patients suffering from acute and chronic pain.

Manufacturers should strengthen their distribution networks through retail and online pharmacies, as these two sectors are projected for high growth in the controlled substance market. Likewise, there is scope for increased market growth in Europe and Asia Pacific, owing to improvements in the healthcare infrastructure in both these regions.

Global Controlled Substance Market: Description

  • Controlled substances are drugs or chemicals that are controlled under the Controlled Substance Act (CSA). The manufacture, possession, or use of these drugs is regulated by a government. These are illegal drugs that can have a detrimental effect on a person's health and welfare. As a result, federal and state governments have regulated these substances. However, if someone has properly prescribed and lawfully purchased one of these substances, they are exempted from prosecution.
  • These substances are used for assistance in the treatment of several types of neurological disorders, as well as in drug research.
  • The demand for controlled substances has been increasing due to the rise in the number of people suffering from various ailments, such as chronic pain. Drugs such as opioids are the most effective analgesics for severe pain, and the mainstay of acute and terminal cancer pain treatments. The development of existing controlled substance molecules in different dosages is boosting their demand in the prescription market. For instance, amphetamine chewable tablets in various formulations create the demand for controlled substances to treat diseases such as ADHD, which affects millions of children across the world.
  • The global controlled substance market was valued at ~US$ 64 Bn in 2018, and is projected to reach a value of ~US$ 115 Bn by 2027, expanding at a CAGR of ~7% during the forecast period of 2019 to 2027.

Controlled Substance Market: Drivers

  • The high incidence rate of chronic pain among the geriatric population across the globe is one of the factors that increases the demand for the use of controlled substances. Several categories of pain medications are available; opioid analgesics are FDA-approved for moderate to severe pain, and effectively work in pain management.
  • The high rate of attention deficit hyperactivity disorder (ADHD) among children is putting more pressure for new drug formulations based on controlled substances. This is creating growth opportunities for controlled drugs, such as opioids and stimulants, in the controlled substance market.
  • The introduction of new products would expand the controlled substance market, while providing more options for effective treatment. Drugs such as amphetamine, in high concentration, that are available in the market in different forms, can be easily addictive if taken for a long time, especially by adolescents. Several pharmaceutical companies are taking efforts to push in new products based on controlled substances in the market, to provide better treatment options with low concentration to people who suffer from diseases such as sleep disorder and ADHD. For instance, in 2016, Neos Therapeutics Inc. launched a new candy-flavored amphetamine chewable tablet in the controlled substance market to treat ADHD patients.
  • Oxycodone exhibits better analgesic efficacy than fentanyl, and comparable efficacy to morphine. In terms of patient satisfaction, higher satisfaction levels were observed with oxycodone in different studies, which has resulted in increased sales across the globe.
  • Amphetamine IR and ER formulation development is one major trend observed, which shows promising growth in the next few years due to a number of upcoming launches by several players for specific indications.
  • Overall growth of the controlled substance market can be ascribed to rise in the prevalence of diseases which need controlled substances to treat them. Hence, overall increase in the patient pool has led to growth of the global controlled substance market.
  • New product approvals such as cocaine-based, C-Topical solutions or upcoming launches such as intranasal fentanyl sprays for cancer pain are some of the evolving trends in this industry, and can be growing factors for the overall controlled substance market.

Global Controlled Substance Market: Prominent Segments

  • Rise in attention deficit hyperactivity disorder prevalence and recently launched products in this category are some of the major factors expected to drive the ADHD segment in the global controlled substance market in terms of application.
  • Based on distribution channel, the retail pharmacies segment is likely to be a highly lucrative segment during the forecast period, owing to a rise in the number of retail pharmacies, especially in the Asia Pacific region.

Global Controlled Substance Market: Competition Landscape

  • Key players analyzed in this report on the global controlled substance market are -
    • F. Hoffmann-La Roche AG
    • AbbVie, Inc.
    • Mallinckrodt plc
    • Pfizer, Inc.
    • Sun Pharmaceuticals Ltd.
    • Ampac Fine Chemicals
    • GW Pharmaceuticals plc
    • Merck & Co., Inc.
    • Lannett
    • Teva Pharmaceutical Ltd.
  • Each of these players in the controlled substance market have been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
  • Strategic mergers & acquisitions, new product launches, and emphasis on research & development are some of the key strategies adopted by major players in the global controlled substance market.
    • For instance, in 2016, Teva Pharmaceuticals Ltd. acquired Activis Pharma, an Ireland-based leading opioid manufacturer, to increase its presence in the controlled substance market.
    • In December, 2017, Genus Lifesciences, Inc., received FDA approval for its product - GOPRELTO nasal solution, 4% (cocaine hydrochloride), for the induction of local anesthesia of the mucous membranes when performing diagnostic procedures and surgeries on or through the nasal cavities in adults.

Global Controlled Substance Market - Segmentation

TMR’s study on the global controlled substance market includes information divided into four sections - drug, application, distribution channel, and region. Changing industry trends and other crucial market dynamics associated with these sections of the global controlled substance market have been discussed in detail.

Drug

  • Opioids
  • Stimulants
  • Depressants
  • Cannabinoids

Application

  • ADHD
  • Pain Management
  • Depression
  • Sleep Disorder
  • Cough Suppression
  • Anxiety
  • Seizure
  • Others

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

What is the total market worth of controlled substance market?

Controlled substance Market to reach a value of ~US$ 115 Bn by 2027

What is the anticipated CAGR of the controlled substance market in the forecast period?

Controlled substance Market is expected to expand at a CAGR of ~7% during the forecast period of 2019 to 2027

What are the key driving factors for the growth of the controlled substance market?

Controlled substance Market is driven by high incidence rate of chronic pain among the geriatric population across the globe

Which is the rising prominent segment in the controlled substance market?

North America accounted for a major share of the global controlled substance market

Who are the key players in the controlled substance market?

Key players in the global controlled substance market include F. Hoffmann-La Roche AG, AbbVie, Inc., Mallinckrodt plc, Pfizer, Inc., Sun Pharmaceuticals Ltd

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary : Global Controlled Substance Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Class Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Controlled Substance Market Analysis and Forecasts, 2017–2027

            4.4.1. Market Revenue Projections (US$ Mn)

    5. Market Outlook

        5.1. Pipeline Analysis

        5.2. Key Merger & Acquisition

        5.3. Regulatory Scenario

    6. Global Controlled Substance Market Analysis and Forecasts, by Drug, 2017-2027 

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Drug, 2017–2027

            6.3.1. Opioids

                6.3.1.1. Codeine

                6.3.1.2. Morphine

                6.3.1.3. Fentanyl

                6.3.1.4. Hydrocodone

                6.3.1.5. Tramadol

                6.3.1.6. Oxycodone

                6.3.1.7. Others

            6.3.2. Stimulants

                6.3.2.1. Amphetamine

                6.3.2.2. Methylphenidate

                6.3.2.3. Dextroamphetamine

                6.3.2.4. Methamphetamine

                6.3.2.5. Modafinil

                6.3.2.6. Others

            6.3.3. Depressants

                6.3.3.1. Barbiturates

                6.3.3.2. Benzodiazepines

            6.3.4. Cannabinoids

        6.4.  Market Attractiveness, by Drug 

    7. Global Controlled Substance Market Analysis and Forecasts, by Application, 2017-2027 

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Application, 2017–2027

            7.3.1. ADHD

            7.3.2. Pain Management

            7.3.3. Depression

            7.3.4. Sleep Disorder

            7.3.5. Cough Suppression

            7.3.6. Anxiety

            7.3.7. Seizure

            7.3.8. Others

        7.4.  Market Attractiveness, by Application 

    8. Global Controlled Substance Market Analysis and Forecasts, by Distribution Channel

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast, by Distribution Channel, 2017–2027

            8.3.1. Hospital Pharmacies

            8.3.2. Retail Pharmacies

            8.3.3. Online Pharmacies

        8.4. Market Attractiveness, by Application

    9. Global Controlled Substance Market Analysis and Forecasts, by Region, 2017-2027

        9.1. Key Findings

        9.2. Market Value Forecast, by Region

            9.2.1. North America 

            9.2.2. Europe 

            9.2.3. Asia Pacific 

            9.2.4. Latin America 

            9.2.5. Middle East & Africa 

        9.3. Market Attractiveness, by Region

    10. North America Controlled Substance Market Analysis and Forecast, 2017-2027

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Drug, 2017–2027

            10.2.1. Opioids

                10.2.1.1. Codeine

                10.2.1.2. Morphine

                10.2.1.3. Fentanyl

                10.2.1.4. Hydrocodone

                10.2.1.5. Tramadol

                10.2.1.6. Oxycodone

                10.2.1.7. Others

            10.2.2. Stimulants

                10.2.2.1. Amphetamine

                10.2.2.2. Methylphenidate

                10.2.2.3. Dextroamphetamine

                10.2.2.4. Methamphetamine

                10.2.2.5. Modafinil

                10.2.2.6. Others

            10.2.3. Depressants

                10.2.3.1. Barbiturates

                10.2.3.2. Benzodiazepines

            10.2.4. Cannabinoids

        10.3. Market Value Forecast, by Application, 2017-2027

            10.3.1. ADHD

            10.3.2. Pain Management

            10.3.3. Depression

            10.3.4. Sleep Disorder

            10.3.5. Cough Suppression

            10.3.6. Anxiety

            10.3.7. Seizure

            10.3.8. Others

        10.4. Market Value Forecast, by Distribution Channel, 2017-2027

            10.4.1. Hospital Pharmacies

            10.4.2. Retail Pharmacies

            10.4.3. Online Pharmacies

        10.5. Market Value Forecast, by Country, 2017-2027 

            10.5.1. U.S.

            10.5.2. Canada

        10.6. Market Attractiveness Analysis 

            10.6.1. By Drug 

            10.6.2. By Application 

            10.6.3. By Distribution Channel

            10.6.4. By Country

    11. Europe Controlled Substance Market Analysis and Forecast, 2017-2027

        11.1. Introduction

            11.1.1. Key Finding

        11.2. Market Value Forecast, by Drug, 2017-2027

            11.2.1. Opioids

                11.2.1.1. Codeine

                11.2.1.2. Morphine

                11.2.1.3. Fentanyl

                11.2.1.4. Hydrocodone

                11.2.1.5. Tramadol

                11.2.1.6. Oxycodone

                11.2.1.7. Others

            11.2.2. Stimulants 

                11.2.2.1. Amphetamine

                11.2.2.2. Methylphenidate

                11.2.2.3. Dextroamphetamine

                11.2.2.4. Methamphetamine

                11.2.2.5. Modafinil

                11.2.2.6. Others

            11.2.3. Depressants

                11.2.3.1. Barbiturates

                11.2.3.2. Benzodiazepines

            11.2.4. Cannabinoids

        11.3. Market Value Forecast, by Application, 2017-2027

            11.3.1. ADHD

            11.3.2. Pain Management

            11.3.3. Depression

            11.3.4. Sleep Disorder

            11.3.5. Cough Suppression

            11.3.6. Anxiety

            11.3.7. Seizure

            11.3.8. Others

        11.4. Market Value Forecast, by Distribution Channel, 2017-2027

            11.4.1. Hospital Pharmacies

            11.4.2. Retail Pharmacies

            11.4.3. Online Pharmacies

        11.5. Market Value Forecast, by Country/Sub-region, 2017-2027

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Italy

            11.5.5. Spain

            11.5.6. Rest of Europe

        11.6. Market Attractiveness Analysis 

            11.6.1. By Drug 

            11.6.2. By Application 

            11.6.3. By Distribution Channel

            11.6.4. By Country/Sub-region

    12. Asia Pacific Controlled Substance Market Analysis and Forecast, 2017-2027

        12.1. Introduction

            12.1.1. Key Finding

        12.2. Market Value Forecast, by Drug, 2017-2027

            12.2.1. Opioids

                12.2.1.1. Codeine

                12.2.1.2. Morphine

                12.2.1.3. Fentanyl

                12.2.1.4. Hydrocodone

                12.2.1.5. Tramadol

                12.2.1.6. Oxycodone

                12.2.1.7. Others

            12.2.2. Stimulants 

                12.2.2.1. Amphetamine

                12.2.2.2. Methylphenidate

                12.2.2.3. Dextroamphetamine

                12.2.2.4. Methamphetamine

                12.2.2.5. Modafinil

                12.2.2.6. Others

            12.2.3. Depressants

                12.2.3.1. Barbiturates

                12.2.3.2. Benzodiazepines

            12.2.4. Cannabinoids 

        12.3. Market Value Forecast, by Application, 2017-2027

            12.3.1. ADHD

            12.3.2. Pain Management

            12.3.3. Depression

            12.3.4. Sleep Disorder

            12.3.5. Cough Suppression

            12.3.6. Anxiety

            12.3.7. Seizure

            12.3.8. Others

        12.4. Market Value Forecast, by Distribution Channel, 2017-2027

            12.4.1. Hospital Pharmacies

            12.4.2. Retail Pharmacies

            12.4.3. Online Pharmacies

        12.5. Market Value Forecast, by Country/Sub-region, 2017-2027

            12.5.1. China

            12.5.2. Japan

            12.5.3. India

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific

        12.6. Market Attractiveness Analysis 

            12.6.1. By Drug 

            12.6.2. By Application 

            12.6.3. By Distribution Channel

            12.6.4. By Country/Sub-region

    13. Latin America Controlled Substance Market Analysis and Forecast, 2017-2027

        13.1. Introduction

            13.1.1. Key Finding

        13.2. Market Value Forecast, by Drug, 2017-2027

            13.2.1. Opioids

                13.2.1.1. Codeine

                13.2.1.2. Morphine

                13.2.1.3. Fentanyl

                13.2.1.4. Hydrocodone

                13.2.1.5. Tramadol

                13.2.1.6. Oxycodone

                13.2.1.7. Others

            13.2.2. Stimulants 

                13.2.2.1. Amphetamine

                13.2.2.2. Methylphenidate

                13.2.2.3. Dextroamphetamine

                13.2.2.4. Methamphetamine

                13.2.2.5. Modafinil

                13.2.2.6. Others

            13.2.3. Depressants

                13.2.3.1. Barbiturates

                13.2.3.2. Benzodiazepines

            13.2.4. Cannabinoids

        13.3. Market Value Forecast, by Application, 2017-2027

            13.3.1. ADHD

            13.3.2. Pain Management

            13.3.3. Depression

            13.3.4. Sleep Disorder

            13.3.5. Cough Suppression

            13.3.6. Anxiety

            13.3.7. Seizure

            13.3.8. Others

        13.4. Market Value Forecast, by Distribution Channel, 2017-2027

            13.4.1. Hospital Pharmacies

            13.4.2. Retail Pharmacies

            13.4.3. Online Pharmacies

        13.5. Market Value Forecast by Country/Sub-region, 2017-2027

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

        13.6. Market Attractiveness Analysis 

            13.6.1. By Drug 

            13.6.2. By Application 

            13.6.3. By Distribution Channel

            13.6.4. By Country/Sub-region

    14. Middle East & Africa Controlled Substance Market Analysis and Forecast, 2017-2027

        14.1. Introduction

            14.1.1. Key Finding

        14.2. Market Value Forecast, by Drug, 2017-2027

            14.2.1. Opioids

                14.2.1.1. Codeine

                14.2.1.2. Morphine

                14.2.1.3. Fentanyl

                14.2.1.4. Hydrocodone

                14.2.1.5. Tramadol

                14.2.1.6. Oxycodone

                14.2.1.7. Others

            14.2.2. Stimulants 

                14.2.2.1. Amphetamine

                14.2.2.2. Methylphenidate

                14.2.2.3. Dextroamphetamine

                14.2.2.4. Methamphetamine

                14.2.2.5. Modafinil

                14.2.2.6. Others

            14.2.3. Depressants

                14.2.3.1. Barbiturates

                14.2.3.2. Benzodiazepines

            14.2.4. Cannabinoids 

        14.3. Market Value Forecast, by Application, 2017-2027

            14.3.1. ADHD

            14.3.2. Pain Management

            14.3.3. Depression

            14.3.4. Sleep Disorder

            14.3.5. Cough Suppression

            14.3.6. Anxiety

            14.3.7. Seizure

            14.3.8. Others

        14.4. Market Value Forecast, by Distribution Channel, 2017-2027

            14.4.1. Hospital Pharmacies

            14.4.2. Retail Pharmacies

            14.4.3. Online Pharmacies

        14.5. Market Value Forecast, by Country/Sub-region, 2017-2027

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Rest of Middle East & Africa

        14.6. Market Attractiveness Analysis 

            14.6.1. By Drug 

            14.6.2. By Application 

            14.6.3. By Distribution Channel

            14.6.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player – Competition Matrix (By Tier and Size of companies)

        15.2. Market Position/Ranking Analysis by Company (2018)

        15.3. Company Profiles

            15.3.1. F. Hoffmann-La Roche AG

                15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.1.2. Company Financials

                15.3.1.3. Growth Strategies

                15.3.1.4. SWOT Analysis

            15.3.2. AbbVie, Inc.

                15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.2.2. Company Financials

                15.3.2.3. Growth Strategies

                15.3.2.4. SWOT Analysis

            15.3.3. Mallinckrodt plc

                15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.3.2. Company Financials

                15.3.3.3. Growth Strategies

                15.3.3.4. SWOT Analysis

            15.3.4. Pfizer, Inc.

                15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.4.2. Company Financials

                15.3.4.3. Growth Strategies

                15.3.4.4. SWOT Analysis

            15.3.5. Sun Pharmaceutical Ltd.

                15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.5.2. Company Financials

                15.3.5.3. Growth Strategies

                15.3.5.4. SWOT Analysis

            15.3.6. Ampac Fine Chemicals

                15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.6.2. Company Financials

                15.3.6.3. Growth Strategies

                15.3.6.4. SWOT Analysis

            15.3.7. GW Pharmaceuticals plc

                15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.7.2. Company Financials

                15.3.7.3. Growth Strategies

                15.3.7.4. SWOT Analysis

            15.3.8. Merck & Co., Inc.

                15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.8.2. Company Financials

                15.3.8.3. Growth Strategies

                16.3.8.4. SWOT Analysis

    List of Tables

    Table 01: Global Controlled Substance Market Value (US$ Mn) Forecast, by Drug, 2017–2027

    Table 02: Global Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Opioids), 2017–2027

    Table 03: Global Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Stimulants), 2017–2027

    Table 04: Global Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Depressants), 2017–2027

    Table 05: Global Controlled Substance Market Value (US$ Mn) Forecast, by Application, 2017–2027

    Table 06: Global Controlled Substance Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 07: Global Controlled Substance Market Value (US$ Mn) Forecast, by Region, 2017–2027

    Table 08: North America Controlled Substance Market Value (US$ Mn) Forecast, by Country, 2017–2027

    Table 09: North America Controlled Substance Market Value (US$ Mn) Forecast, by Drug, 2017–2027

    Table 10: North America Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Opioids), 2017–2027

    Table 11: North America Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Stimulants), 2017–2027

    Table 12: North America Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Depressants), 2017–2027

    Table 13: North America Controlled Substance Market Value (US$ Mn) Forecast, by Application, 2017–2027

    Table 14: North America Controlled Substance Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 15: Europe Controlled Substance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 16: Europe Controlled Substance Market Value (US$ Mn) Forecast, by Drug, 2017–2027

    Table 17: Europe Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Opioids), 2017–2027

    Table 18: Europe Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Stimulants), 2017–2027

    Table 19: Europe Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Depressants), 2017–2027

    Table 20: Europe Controlled Substance Market Value (US$ Mn) Forecast, by Application, 2017–2027

    Table 21: Europe Controlled Substance Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 22: Asia Pacific Controlled Substance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 23: Asia Pacific Controlled Substance Market Value (US$ Mn) Forecast, by Drug, 2017–2027

    Table 24: Asia Pacific Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Opioids), 2017–2027

    Table 25: Asia Pacific Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Stimulants), 2017–2027

    Table 26: Asia Pacific Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Depressants), 2017–2027

    Table 27: Asia Pacific Controlled Substance Market Value (US$ Mn) Forecast, by Application, 2017–2027

    Table 28: Asia Pacific Controlled Substance Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 29: Latin America Controlled Substance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 30: Latin America Controlled Substance Market Value (US$ Mn) Forecast, by Drug, 2017–2027

    Table 31: Latin America Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Opioids), 2017–2027

    Table 32: Latin America Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Stimulants), 2017–2027

    Table 33: Latin America Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Depressants), 2017–2027

    Table 34: Latin America Controlled Substance Market Value (US$ Mn) Forecast, by Application, 2017–2027

    Table 35: Latin America Controlled Substance Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 36: Middle East & Africa Controlled Substance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 37: Middle East & Africa Controlled Substance Market Value (US$ Mn) Forecast, by Drug, 2017–2027

    Table 38: Middle East & Africa Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Opioids), 2017–2027

    Table 39: Middle East & Africa Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Stimulants), 2017–2027

    Table 40: Middle East & Africa Controlled Substance Market Value (US$ Mn) Forecast, by Drug (Depressants), 2017–2027

    Table 41: Middle East & Africa Controlled Substance Market Value (US$ Mn) Forecast, by Application, 2017–2027

    Table 42: Middle East & Africa Controlled Substance Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    List of Figures

    Figure 01: Global Controlled Substance Market Value (US$ Mn) and Distribution, by Region, 2018 and 2027

    Figure 02: Market Opportunity Map, by Drug Type, 2018

    Figure 03: Global Controlled Substance Market Value (US$ Mn) Forecast, 2017–2027

    Figure 04: Global Controlled Substance Market Value Share, by Drug (2018)

    Figure 05: Global Controlled Substance Market Value Share, by Application (2018)

    Figure 06: Global Controlled Substance Market Value Share, by Distribution Channels (2018)

    Figure 07: Global Controlled Substance Market Value Share, by Region (2018)

    Figure 08: Global Controlled Substance Market Value Share Analysis, by Drug, 2018 and 2027

    Figure 09: Global Controlled Substance Market Revenue (US$ Mn) by Opioids, 2017-2027

    Figure 10: Global Controlled Substance Market Revenue (US$ Mn) by Stimulants, 2017-2027

    Figure 11: Global Controlled Substance Market Revenue (US$ Mn) by Depressants, 2017-2027

    Figure 12: Global Controlled Substance Market Revenue (US$ Mn) by Cannabinoids, 2017-2027

    Figure 13: Global Controlled Substance Market Attractiveness Analysis, by Drug, 2019–2027

    Figure 14: Global Controlled Substance Market Value Share Analysis, by Application, 2018 and 2027

    Figure 15: Global Controlled Substance Market Value (US$ Mn), by ADHD, 2017–2027

    Figure 16: Global Controlled Substance Market Value (US$ Mn), by Pain Management, 2017–2027

    Figure 17: Global Controlled Substance Market Value (US$ Mn), by Depression, 2017–2027

    Figure 18: Global Controlled Substance Market Value (US$ Mn), by Sleep Disorder, 2017–2027

    Figure 19: Global Controlled Substance Market Value (US$ Mn), by Cough Suppression, 2017–2027

    Figure 20: Global Controlled Substance Market Value (US$ Mn), by Anxiety, 2017–2027

    Figure 21: Global Controlled Substance Market Value (US$ Mn), by Seizure, 2017–2027

    Figure 22: Global Controlled Substance Market Value (US$ Mn), by Others, 2017–2027

    Figure 23: Global Controlled Substance Market Attractiveness, by Application, 2019–2027

    Figure 24: Global Controlled Substance Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 25: Global Controlled Substance Market Revenue (US$ Mn) by Hospital Pharmacies, 2017-2027

    Figure 26: Global Controlled Substance Market Revenue (US$ Mn) Retail Pharmacies, 2017-2027

    Figure 27: Global Controlled Substance Market Revenue (US$ Mn) Online Pharmacies, 2017-2027

    Figure 28: Global Controlled Substance Market Attractiveness Analysis, by Distribution Channel, 2019–2027

    Figure 29: Global Controlled Substance Market Value Share Analysis, by Region, 2018 and 2027

    Figure 30: Global Controlled Substance Market Attractiveness Analysis, by Region, 2019–2027

    Figure 31: North America Controlled Substance Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

    Figure 32: North America Controlled Substance Market Value Share, by Country, 2018 and 2027

    Figure 33: North America Controlled Substance Market Attractiveness, by Country, 2019–2027

    Figure 34: North America Controlled Substance Market Value Share, by Drug, 2018 and 2027

    Figure 35: North America Controlled Substance Market Attractiveness, by Drug, 2019–2027

    Figure 36: North America Controlled Substance Market Value Share, by Application, 2018 and 2027

    Figure 37: North America Controlled Substance Market Attractiveness, by Application, 2019–2027

    Figure 38: North America Controlled Substance Market Value Share, by Distribution Channel, 2018 and 2027

    Figure 39: North America Controlled Substance Market Attractiveness, by Distribution Channel, 2019–2027

    Figure 40: Europe Controlled Substance Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

    Figure 41: Europe Controlled Substance Market Value Share, by Country/Sub-region, 2018 and 2027

    Figure 42: Europe Controlled Substance Market Attractiveness, by Country/Sub-region, 2019–2027

    Figure 43: Europe Controlled Substance Market Value Share, by Drug, 2018 and 2027

    Figure 44: Europe Controlled Substance Market Attractiveness, by Drug, 2019–2027

    Figure 45: Europe Controlled Substance Market Value Share, by Application, 2018 and 2027

    Figure 46: Europe Controlled Substance Market Attractiveness, by Application, 2019–2027

    Figure 47: Europe Controlled Substance Market Value Share, by Distribution Channel, 2018 and 2027

    Figure 48: Europe Controlled Substance Market Attractiveness, by Distribution Channel, 2019–2027

    Figure 49: Asia Pacific Controlled Substance Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

    Figure 50: Asia Pacific Controlled Substance Market Value Share, by Country/Sub-region, 2018 and 2027

    Figure 51: Asia Pacific Controlled Substance Market Attractiveness, by Country/Sub-region, 2019–2027

    Figure 52: Asia Pacific Controlled Substance Market Value Share, by Drug, 2018 and 2027

    Figure 53: Asia Pacific Controlled Substance Market Attractiveness, by Drug, 2019–2027

    Figure 54: Asia Pacific Controlled Substance Market Value Share, by Application, 2018 and 2027

    Figure 55: Asia Pacific Controlled Substance Market Attractiveness, by Application, 2019–2027

    Figure 56: Asia Pacific Controlled Substance Market Value Share, by Distribution Channel, 2018 and 2027

    Figure 57: Asia Pacific Controlled Substance Market Attractiveness, by Distribution Channel, 2019–2027

    Figure 58: Latin America Controlled Substance Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

    Figure 59: Latin America Controlled Substance Market Value Share, by Country/Sub-region, 2018 and 2027

    Figure 60: Latin America Controlled Substance Market Attractiveness, by Country/Sub-region, 2019–2027

    Figure 61: Latin America Controlled Substance Market Value Share, by Drug, 2018 and 2027

    Figure 62: Latin America Controlled Substance Market Attractiveness, by Drug, 2019–2027

    Figure 63: Latin America Controlled Substance Market Value Share, by Application, 2018 and 2027

    Figure 64: Latin America Controlled Substance Market Attractiveness, by Application, 2019–2027

    Figure 65: Latin America Controlled Substance Market Value Share, by Distribution Channel, 2018 and 2027

    Figure 66: Latin America Controlled Substance Market Attractiveness, by Distribution Channel, 2019–2027

    Figure 67: Middle East & Africa Controlled Substance Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

    Figure 68: Middle East & Africa Controlled Substance Market Value Share, by Country/Sub-region, 2018 and 2027

    Figure 69: Middle East & Africa Controlled Substance Market Attractiveness, by Country/Sub-region, 2019–2027

    Figure 70: Middle East & Africa Controlled Substance Market Value Share, by Drug, 2018 and 2027

    Figure 71: Middle East & Africa Controlled Substance Market Attractiveness, by Drug, 2019–2027

    Figure 72: Middle East & Africa Controlled Substance Market Value Share, by Application, 2018 and 2027

    Figure 73: Middle East & Africa Controlled Substance Market Attractiveness, by Application, 2019–2027

    Figure 74: Middle East & Africa Controlled Substance Market Value Share, by Distribution Channel, 2018 and 2027

    Figure 75: Middle East & Africa Controlled Substance Market Attractiveness, by Distribution Channel, 2019–2027

    Figure 76: Market Position/Ranking Analysis, 2018, by Tier and Size of the Company

Copyright © Transparency Market Research, Inc. All Rights reserved